These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 2665626

  • 1. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH, Sage JI.
    Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
    [Abstract] [Full Text] [Related]

  • 2. Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease.
    Mark MH, Sage JI.
    Ann Clin Lab Sci; 1989; 19(6):415-21. PubMed ID: 2690730
    [Abstract] [Full Text] [Related]

  • 3. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
    Feldman RG, Mosbach PA, Kelly MR, Thomas CA, Saint Hilaire MH.
    Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
    [Abstract] [Full Text] [Related]

  • 4. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S.
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [Abstract] [Full Text] [Related]

  • 5. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA, Nelson MV, Berchou RC, Galloway MP, Kesaree N, Kareti D, Schlick P.
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
    Jankovic J, Schwartz K, Vander Linden C.
    Mov Disord; 1989 Nov; 4(4):303-9. PubMed ID: 2682215
    [Abstract] [Full Text] [Related]

  • 7. Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
    Rodnitzky RL, Dickins QS, Dobson J.
    Neurology; 1989 Nov; 39(11 Suppl 2):92-5; discussion 95. PubMed ID: 2586769
    [Abstract] [Full Text] [Related]

  • 8. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
    Goetz CG, Tanner CM, Gilley DW, Klawans HL.
    Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
    [Abstract] [Full Text] [Related]

  • 9. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK, Rinne JO.
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [Abstract] [Full Text] [Related]

  • 10. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
    Deleu D, Jacques M, Michotte Y, Ebinger G.
    Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
    [Abstract] [Full Text] [Related]

  • 11. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM, Hoey M, Kutt H, McDowell FH.
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [Abstract] [Full Text] [Related]

  • 12. Sinemet CR in Parkinson's disease.
    Pfeiffer RF, Wilken KE, Glaeske CS, Hofman R.
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [Abstract] [Full Text] [Related]

  • 13. An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
    Bush DF, Liss CL, Morton A.
    Neurology; 1989 Nov; 39(11 Suppl 2):101-4; discussion 105. PubMed ID: 2685646
    [Abstract] [Full Text] [Related]

  • 14. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA, Gilhus NE.
    Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [Abstract] [Full Text] [Related]

  • 15. The use of Sinemet CR in the management of mild to moderate Parkinson's disease.
    Rodnitzky RL.
    Neurology; 1992 Jan; 42(1 Suppl 1):44-50; discussion 57-60. PubMed ID: 1549201
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, Smith ME, Titus DC.
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [Abstract] [Full Text] [Related]

  • 17. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
    Cedarbaum JM, Kutt H, McDowell FH.
    Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762
    [Abstract] [Full Text] [Related]

  • 18. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
    Rondot P, Ziegler M, Aymard N, Teinturier A.
    Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
    [Abstract] [Full Text] [Related]

  • 19. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
    Hutton JT, Morris JL, Román GC, Imke SC, Elias JW.
    Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259
    [Abstract] [Full Text] [Related]

  • 20. Trial of Sinemet CR4 in patients with Parkinson's disease.
    Anderson TJ, Ewer TC, Gilchrist NL, Donaldson IM.
    N Z Med J; 1992 Mar 11; 105(929):81-2. PubMed ID: 1545941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.